Robert Spraggins

This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.

Researcher

UAMS

Also affiliated: Louisiana State University in Shreveport (2021); University of Arkansas Medical Center (2025); Central Arkansas Veterans Healthcare System (2026)

Faculty Researcher

1 h-index 14 pubs 26 cited

Research Areas

OverviewAI-generated summary

Robert Spraggins' research primarily investigates cardiovascular outcomes in diverse patient populations, often utilizing real-world data analysis. His work includes examining the association between cardiovascular events and procedures such as percutaneous coronary intervention, with or without preceding coronary CT angiography. Spraggins has also studied the cardiovascular impact of post-traumatic stress disorder, the efficacy of combined SGLT2 inhibitor and GLP1 receptor agonist therapies in individuals with type 2 diabetes, and the cardiovascular outcomes associated with GLP-1RA therapy in non-diabetic obese patients with metabolic dysfunction-associated steatotic liver disease. Additional research areas include comparing the real-world cardiovascular outcomes of Inclisiran versus PCSK9 monoclonal antibody therapy in hyperlipidemia and evaluating the cardioprotective effects of beta-blocker therapy post-myocardial infarction. His publications also touch upon the prevalence of specific electrocardiographic findings during the COVID-19 pandemic.

Metrics

h-index: 1
Publications: 14
Citations: 26

Selected Publications

AI-enhanced ECG for acute coronary syndrome triage: A state-of-the-art review (2026)

Cardiovascular revascularization medicine DOI OpenAlex
Examining the association between cardiovascular outcomes in individuals undergoing percutaneous coronary intervention with or without a preceding coronary CT angiogram (2026)

European Heart Journal - Imaging Methods and Practice 1 citation DOI OpenAlex
26-A-11242-ACC REAL-WORLD CARDIOVASCULAR OUTCOMES OF COMBINED SGLT2 INHIBITOR AND GLP1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES INDIVIDUALS (2026)

Journal of the American College of Cardiology DOI OpenAlex
26-A-15959-ACC CARDIOVASCULAR OUTCOMES OF GLP-1RA THERAPY IN OBESE NON-DIABETIC PATIENTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE: A REAL-WORLD ANALYSIS (2026)

Journal of the American College of Cardiology DOI OpenAlex
1200.03 Real-World Cardiovascular Outcomes of Inclisiran Versus PCSK9 Monoclonal Antibodies Therapy in Individuals with Hyperlipidemia (2026)

JACC: Cardiovascular Interventions DOI OpenAlex
Prevalence and Most Commonly Encountered QRS Fragmentation Morphology and Early Repolarization ST-Segment Changes During the Height of the COVID-19 Pandemic: A Single-Center Experience (2026)

Cureus DOI OpenAlex
HYPERTENSIVE RESPONSE DURING DOBUTAMINE STRESS ECHOCARDIOGRAPHY AND RISK OF NEW ONSET HEART FAILURE (2025)

Journal of the American College of Cardiology DOI OpenAlex
SIGNIFICANCE OF ISCHEMIC ELECTROCARDIOGRAM CHANGES IN THE SETTING OF NORMAL IMAGING IN DOBUTAMINE STRESS ECHOCARDIOGRAPHY (2025)

Journal of the American College of Cardiology DOI OpenAlex
Abstract 16061: Correlation Between Obesity and Ventricular Tachycardia in Individuals With HFrEF: Analysis From the DERIVATE Cohort (2023)

Circulation DOI OpenAlex